Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02845726
Other study ID # CTU 15.010
Secondary ID
Status Completed
Phase N/A
First received July 8, 2016
Last updated January 24, 2018
Start date July 2016
Est. completion date December 2017

Study information

Verified date January 2018
Source Cantonal Hospital of St. Gallen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is performed to analyze various aspects of biofilms on ureteral stents.


Description:

The study is performed to provide a better understanding of the influence of biofilms on ureteral stents on the entire spectrum of stent-associated morbidity.

Moreover, it could provide more detailed knowledge about the correlation of the occurrence of biofilms on ureteral stents and findings in urinary analysis, which could serve as a decision support whether patients with ureteral stents undergoing further interventions (for example ESWL or simple secondary URS) should receive antibiotic prophylaxis.

Correlation of results of urinary bacteriologies (assessed pre- and intraoperatively) and biofilm analysis on stents could provide information if "targeted antibiotic treatment" based on urinary bacteriology only is possible at all.

Correlation of urinary analysis and conventional urinary bacteriology could provide a valuable contribution regarding the prediction of bacteriuria and the necessity of postponing operations.

Additionally, the study is intended to provide an overview over the recent bacterial species that are involved into biofilms on ureteral stents and their resistance to antibiotics. This could provide valuable information about the choice of antibiotics in cases were treatment has to be performed empirically.


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date December 2017
Est. primary completion date September 23, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients temporarily undergoing ureteral stenting

- Informed consent

Exclusion Criteria:

- Bilateral stenting

- Ureteral obstruction due to malignancies

- Additionally performed procedures/operations during stent indwelling time -Cognitively impaired patients

- UTI at the time of stent insertion (>10 to the power of 2 cfu/ml)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Stent examination, urinary analysis, USSQ questionnaire


Locations

Country Name City State
Switzerland Urological Department, Cantonal Hospital of St. Gallen St. Gallen Saint Gallen

Sponsors (1)

Lead Sponsor Collaborator
Cantonal Hospital of St. Gallen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total biofilm mass on ureteral stents. Time of stent removal: Four weeks (range 2-6 weeks) after stent insertion
Primary Assessment of morbidity using the Ureteral Stent Symptom Questionnaire (USSQ) Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion)
Secondary Assessment of morbidity using the Ureteral Stent Symptom Questionnaire (USSQ) One week after stent insertion; Four weeks (range 2-6 weeks) after stent removal.
Secondary Urinary analysis (pH, nitrite, leucocyturia, hematuria). Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion)
Secondary Urine Culture Before study inclusion; Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion); Intraoperatively (during stent removal)
Secondary Rapid immunoassay test for bacteriuria Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion)
Secondary Next generation sequencing of biofilms To identify bacterial species that are involved into biofilms on ureteral stents. Day of stent removal: Four weeks (range 2-6 weeks) after stent insertion
Secondary Number of bacteria on stent surface (cell count as estimated by scanning electron microscopy) Day of stent removal: Four weeks (range 2-6 weeks) after stent insertion
Secondary Number of bacteria on stent surface (determined via quantitative PCR) Day of stent removal: Four weeks (range 2-6 weeks) after stent insertion
See also
  Status Clinical Trial Phase
Completed NCT04092465 - Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)
Not yet recruiting NCT05447611 - Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.
Recruiting NCT00980733 - Efficacy of Micronutrient Fortified Yoghurt in School Children for Health Benefits Phase 3
Completed NCT00400790 - Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane N/A
Completed NCT04542330 - Using BCG to Protect Senior Citizens During the COVID-19 Pandemic Phase 3
Completed NCT03885206 - Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital N/A
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT01631799 - Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia N/A
Recruiting NCT03739944 - Different Surgical Approaches in Patients of Early-stage Cervical Cancer Phase 3
Active, not recruiting NCT03460002 - Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children Phase 4
Active, not recruiting NCT00168610 - Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Phase 4
Completed NCT00168636 - Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality Phase 4
Active, not recruiting NCT00168623 - Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity Phase 4
Completed NCT00168584 - Different Doses of Vitamin A and Childhood Morbidity and Mortality Phase 4
Recruiting NCT06107725 - Maimonides Minocycline in Stroke Study Phase 2/Phase 3
Completed NCT03488680 - Effectiveness of Behavior Change Communication in Improving Feeding Practices, Nutritional and Health Status of Infants N/A
Completed NCT04373291 - Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic Phase 3
Completed NCT04694469 - Comparison of Day-time and Night-time Operations of Supracondylar Humeral Fractures
Completed NCT03607084 - School-based Health Programs on Children's Wellbeing in Lusaka, Zambia N/A
Recruiting NCT05696301 - Interest of Tecartherapy on a Painful Caesarean Section Scar: a Randomized Clinical Trial. N/A